Reed Tuckson's most recent trade in Adverum Biotechnologies Inc was a trade of 10,450 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 17, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Adverum Biotechnologies Inc | Reed V. Tuckson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 10,450 | 10,450 | - | - | Stock Option (Right to Buy) | |
| Henry Schein | Reed V. Tuckson | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 71.14 per share. | 11 Jun 2025 | 487 | 9,943 (0%) | 0% | 71.1 | 34,645 | Common Stock, par value $0.01 per share |
| Henry Schein | Reed V. Tuckson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 2,844 | 10,430 (0%) | 0% | 0 | Common Stock, par value $0.01 per share | |
| Henry Schein | Reed V. Tuckson | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 70.31 per share. | 04 Mar 2025 | 572 | 7,586 (0%) | 0% | 70.3 | 40,217 | Common Stock, par value $0.01 per share |
| Adverum Biotechnologies Inc | Reed V. Tuckson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 10,520 | 10,520 | - | - | Stock Option (Right to Buy) | |
| Henry Schein | Reed V. Tuckson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 2,604 | 8,158 (0%) | 0% | 0 | Common Stock, par value $0.01 per share | |
| Henry Schein | Reed V. Tuckson | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 76.88 per share. | 01 Mar 2024 | 495 | 5,554 (0%) | 0% | 76.9 | 38,056 | Common Stock, par value $0.01 per share |
| Adverum Biotechnologies Inc | Reed Tuckson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Henry Schein | Reed Tuckson | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.15 per share. | 16 Mar 2023 | 446 | 6,049 (0%) | 0% | 78.2 | 34,855 | Common Stock, par value $0.01 per share |
| Henry Schein | Reed Tuckson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 2,250 | 6,495 (0%) | 0% | 0 | Common Stock, par value $0.01 per share | |
| Adverum Biotechnologies Inc | Reed Tuckson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Adverum Biotechnologies Inc | Reed Tuckson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2021 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) |